Microvascular angina

Article written and reviewed by Dr Luca Moretti

Microvascular angina, abbreviated MVA, is a clinical syndrome in which chest pain or ischemic equivalents are attributable to an abnormality of the coronary microcirculation. The large arteries may appear normal or non-obstructive, while arterioles and capillaries do not correctly adapt flow to myocardial demand. The term clinical syndrome is essential. An abnormal microvascular measurement without symptoms is not, by itself, sufficient for this diagnosis.
MVA and coronary microvascular dysfunction are not perfect synonyms. The latter describes a pathophysiological mechanism that may also occur in cardiomyopathies, aortic stenosis, heart failure, myocardial infarction, or after revascularization; the former requires that mechanism to explain an anginal or ischemic presentation. The clinical link must be demonstrated through consistent anatomy, ischemia, and physiology; this distinction prevents every low CFR value from being turned into a symptomatic diagnosis.

The former term “cardiac syndrome X” grouped people with angina, a positive exercise test, and angiographically normal coronary arteries, but included different mechanisms and sometimes nonischemic diagnoses. It is now used only as a historical reference because it identifies neither the type of dysfunction nor the appropriate treatment. Modern terminology distinguishes MVA, vasospastic angina, ANOCA, and INOCA. Endotypes may nevertheless overlap.
The absence of a stenosis to dilate does not make the disorder benign or imaginary. Persistent angina, dyspnea, reduced activity, and repeated healthcare visits cause substantial disability, while prospective studies show a non-negligible risk of events in subgroups with markedly abnormal physiology; a positive diagnosis replaces mere anatomical exclusion. Every new prolonged or unstable pain nonetheless requires the usual urgent assessment.

Etiology, risk factors, pathogenesis, and pathophysiology

The microcirculation comprises prearterioles, arterioles, and capillaries that distribute flow according to local metabolism. As oxygen consumption rises, arteriolar resistance must fall and flow may increase several-fold above rest; an inadequate response exposes the subendocardium in particular to diffuse ischemia. Vasodilatory reserve integrates endothelial function, smooth muscle, and vascular architecture. It does not correspond merely to patency of the epicardial coronary arteries.
In the structural phenotype, the arteriolar lumen may be reduced by inward remodeling, wall hypertrophy, perivascular fibrosis, and capillary rarefaction. Capacity to increase flow falls and minimal resistance during hyperemia is elevated, although histology is not directly available in clinical practice. Arteriolar remodeling is promoted by hypertension, diabetes, aging, and inflammation. A hemodynamic threshold remains a surrogate, not a biopsy.

In the functional phenotype, CFR may be low despite relatively preserved hyperemic resistance. The defect often arises from disproportionately high resting flow, with a smaller apparent margin for increase, and involves metabolic regulation, autonomic tone, and nitric oxide synthase activity; high resting flow does not mean optimal perfusion. Tachycardia, blood pressure, anxiety, anemia, and measurement conditions may amplify the phenomenon.
Microvascular spasm is dynamic vasoconstriction of the arterioles that produces symptoms and ischemic changes without the diagnostic epicardial narrowing of vasospastic angina. It can be provoked with acetylcholine at experienced laboratories and may coexist with impaired adenosine-mediated vasodilation, making classification into exclusive compartments inadequate. Arteriolar vasoconstriction involves smooth-muscle hyperreactivity, the endothelium, and the autonomic nervous system. The response to nitrates is less predictable than in epicardial spasm.

Endothelial dysfunction reduces nitric oxide availability and promotes endothelins, reactive oxygen species, inflammation, and thrombogenicity; an abnormal response to low-dose acetylcholine, however, does not automatically coincide with microvascular spasm, which requires reproduction of symptoms and ischemic signs according to specific criteria. Endothelial function is a related but distinct domain. Adenosine and acetylcholine interrogate different physiological pathways and provide complementary information.
Hypertension, dyslipidemia, smoking, diabetes, obesity, and chronic kidney disease are associated with MVA and CMD but are not present in every patient. Their contribution includes oxidative stress, glycation, inflammation, arteriolar stiffening, rarefaction, and increased myocardial demand; traditional factors guide prevention and treatment of comorbidities. They do not replace functional documentation when the diagnosis remains uncertain.

Autoimmune and inflammatory diseases, including lupus and rheumatoid arthritis, may impair the microcirculation and endothelium through cytokines, autoantibodies, and accelerated atherosclerosis. Early menopause, hypertensive disorders of pregnancy, and psychosocial stress are also associated with vascular risk in women without being univocal causes. The systemic history broadens assessment beyond lipids. Treatment of the underlying disease follows its own evidence and does not automatically promise remission of angina.
Women are overrepresented in MVA cohorts, particularly because they more often have angina without obstruction and have been extensively studied in the WISE and iPOWER programs. MVA nonetheless affects both sexes, and referral differences, vessel size, biological factors, and clinical recognition affect estimates; female sex modifies probability but is not a diagnostic criterion. Quality of life may be worse among women even when event rates are similar.

Repeated ischemia, altered cardiac perception, and central sensitization may contribute to persistent pain; this model does not set organic disease and psychology against each other. An ischemic signal may be amplified, while fear and deconditioning further lower the exertional threshold; nociceptive modulation is considered in refractory cases. Anxiety and depression deserve direct treatment without being used to deny documented coronary physiology.

Pathological anatomy, classification, and progression

The COVADIS clinical classification begins with four domains: symptoms compatible with ischemia, absence of obstructive coronary artery disease, objective evidence of ischemia, and evidence of impaired microvascular function. The system was designed to standardize research and practice, reducing the heterogeneity of the former syndrome X. Definitive MVA requires all four domains. The strength of the diagnosis also depends on the quality with which each is documented.
Permitted symptoms include exertional or rest angina and equivalents such as exertional dyspnea. Absence of obstruction is established with CCTA or coronary angiography showing less than 50 percent diameter reduction, or FFR above 0.80 when a lesion requires functional assessment; non-obstructive disease may nevertheless contain diffuse plaque. The criterion is not equivalent to a perfectly healthy coronary wall.

Objective ischemia may consist of ECG changes during pain or stress-induced symptoms or ischemic changes, with or without a reversible defect in perfusion or wall motion. A positive exercise test alone does not identify the responsible compartment and must be interpreted with anatomy and technical quality. Documentation of ischemia distinguishes the definitive syndrome from a clinical hypothesis alone. Different tests do not have identical sensitivity for global ischemia.
The fourth domain may be satisfied by reduced CFR, elevated microvascular resistance, inducible microvascular spasm, or, in the original definition, slow coronary flow with a TIMI frame count greater than 25. Recent studies show, however, that angiographic slow flow correlates poorly with invasive physiology and must not be used in isolation. Microvascular evidence must be methodologically sound. Qualitative imaging does not replace a measurement when the question requires endotyping.

MVA is considered suspected when symptoms and non-obstructive coronary arteries are present together with either evidence of ischemia alone or evidence of CMD alone; this category is useful in practice and to guide further investigations, but must not be presented to the patient as equivalent in certainty to the definitive form. The diagnostic grade should be stated in the report. Missing, negative, or discordant examinations must be described explicitly.
From a physiological perspective, three endotypes are distinguished: structural, functional, and spastic. The first combines reduced reserve and elevated hyperemic resistance; the second shows reduced reserve with preserved minimal resistance and often high resting flow; the third is demonstrated with acetylcholine. Overlapping endotypes are common. A person may simultaneously have reduced CFR, microvascular spasm, endothelial dysfunction, and epicardial spasm.

Classification into ANOCA and INOCA describes another dimension. ANOCA begins with angina without obstruction, whereas INOCA requires documented ischemia; definitive MVA falls within the INOCA spectrum, whereas suspected MVA may lie within ANOCA before objective evidence is obtained. The clinical taxonomy must not replace the mechanism. Using every acronym as a synonym creates conceptual confusion and poorly targeted therapies.
The course is not linear: symptom frequency, exertional threshold, and drug response may change even without anatomical variation. Blood pressure, heart rate, anemia, menopause, inflammation, sleep, and stress modulate demand and vascular tone; temporal variability explains why a single test may not capture every episode. It does not, however, justify indefinite repetition without a new clinical question.

Non-obstructive plaque, epicardial spasm, and heart disease may appear over time and modify diagnosis and prognosis. A patient previously classified as having MVA may develop a stenosis, myocardial infarction, or heart failure, while others remain primarily limited by chronic symptoms; dynamic follow-up reassesses new signs instead of defending an immutable label. Any abrupt worsening reopens the urgent differential diagnosis.

Clinical manifestations

The most common symptom is chest pressure, tightness, heaviness, or burning provoked by exertion or emotional stress. Location and radiation may resemble angina caused by stenosis, but duration and threshold are often more variable and resolution after exertion may be slow; exertional pain remains an important manifestation. No single quality reliably identifies the microcirculation.
Some episodes occur at rest, at night, or in the hours after exertion, especially when a spastic component is present. Coexistence of exertional and rest pain suggests a mixed phenotype but cannot distinguish microvascular from epicardial spasm without vasomotor assessment; the temporal pattern guides testing. An accurate diary is more informative than generic labels such as atypical pain.

Dyspnea, fatigue, weakness, and reduced activity tolerance may be ischemic equivalents, but have a broad differential diagnosis. Anemia, pulmonary disease, obesity, arrhythmias, valvular heart disease, and HFpEF must be assessed because they may lower the threshold or represent the main cause; exertional dyspnea alone does not satisfy the MVA criteria. Consistency with anatomy, ischemia, and microvascular function is required.
The response to sublingual nitroglycerin is variable. Improvement may occur, but is nonspecific and does not confirm the diagnosis; in purely microvascular forms, nitrates may be less effective or cause headache and hypotension without substantial benefit. The response to nitrates is recorded, not used as sole evidence. Duration of the effect and concomitant medications must be considered.

Palpitations, dizziness, and syncope are not mandatory manifestations and require an independent search for arrhythmias or hemodynamic instability. Overlapping coronary spasm may be accompanied by transient ECG changes, while chronic pain and hypervigilance may heighten awareness of the heartbeat; associated syncope is a sign warranting greater attention. It is not automatically attributed to MVA without documentation.
Physical examination is often normal outside episodes, and the resting ECG may also show no abnormalities; these findings do not exclude an intermittent ischemic syndrome, but require avoidance of excessive conclusions if objective evidence is lacking. Baseline normality is compatible with MVA. Conversely, murmurs, congestion, hypertrophy, or persistent abnormalities shift attention toward associated heart disease.

Functional limitation may be disproportionate to anatomical burden and cause absence from work, avoidance of exercise, and family difficulties. Instruments such as the Seattle Angina Questionnaire quantify frequency, stability, limitation, treatment satisfaction, and quality of life, allowing comparisons over time. The symptom burden is a genuine clinical outcome. It must not be confused with individual risk of myocardial infarction or death.
New prolonged pain, diaphoresis, nausea, severe dyspnea, syncope, or instability requires ECG and troponin assessment according to acute coronary syndrome pathways. A previous diagnosis of MVA does not protect against thrombosis, SCAD, embolism, myocarditis, Takotsubo syndrome, or pulmonary embolism; warning signs take precedence over the usual pattern. The patient must receive clear instructions on when to seek urgent care.

Reflux, esophageal spasm, musculoskeletal pain, pleurisy, asthma, and panic attacks may mimic or coexist with angina. A positive diagnosis of MVA does not make every subsequent episode ischemic, especially when new features or reproducibility on palpation appear; the differential diagnosis remains active during follow-up. Recognizing multiple pain generators avoids both minimization and unnecessary drug escalation.

Investigations and diagnosis

The initial assessment reconstructs symptoms, triggers, vascular factors, medications, and comorbidities; it includes physical examination, ECG, complete blood count, kidney function, glucose, lipids, and targeted tests. Echocardiography assesses ventricular function, hypertrophy, valves, and pressures that may explain or amplify symptoms; the initial work-up excludes urgent and structural causes. It does not yet demonstrate the microvascular mechanism.
CCTA describes stenoses and plaque burden in suitable patients, whereas invasive coronary angiography is indicated when probability, symptoms, or tests warrant it. A stenosis below 50 percent may be non-obstructive but biologically relevant; for intermediate lesions, FFR or nonhyperemic indices clarify significance. Epicardial patency is a necessary condition for classic MVA. It does not directly visualize arterioles and capillaries.

CFR is the ratio of flow or velocity during hyperemia to that at rest. Healthy values are often above 3, but the diagnostic threshold depends on the technique: COVADIS permits a cutoff of 2.0-2.5 or lower according to the method, whereas the 2024 ESC guidelines consider CFR below 2.5 with Doppler or thermodilution abnormal. Reduced CFR is a global measurement. It may reflect diffuse epicardial disease, high resting flow, or inadequate hyperemic flow.
CFR varies with heart rate, blood pressure, age, sex, caffeine, medications, and the intensity of hyperemia. Thermodilution and Doppler show only modest correlation: the former tends to overestimate reserve relative to the latter, and a thermodilution threshold of 2.0 has limited sensitivity. This method dependence requires the technique and conditions to be reported. Values near the threshold are not binary truths and must be integrated into the clinical picture.

Thermodilution IMR is derived from the product of distal pressure and mean transit time during hyperemia; a value of 25 or greater commonly indicates elevated resistance. It is more specific to the microcirculation and less dependent on resting flow than CFR, but requires an invasive guidewire and adequate hyperemia. Elevated IMR supports a structural phenotype. Collaterals, stenosis, sampled territory, and technique may modify interpretation.
HMR uses Doppler and is calculated by dividing distal pressure by average peak velocity during hyperemia. The 2024 ESC guidelines indicate a value above 2.5 mmHg·s/cm as abnormal, but the literature and protocols have used different thresholds; Doppler resistance is not interchangeable with IMR. The signal is operator-dependent and is acquired in only one territory at a time.

PET quantifies absolute myocardial flow at rest and during vasodilation with validated tracers and calculates myocardial flow reserve. A value below 2.0 is commonly considered abnormal and has robust prognostic associations after relevant stenosis and diffuse disease have been excluded; quantitative PET is the best-validated noninvasive reference. Radiation, cost, availability, tracer, and software limit access and comparability.
Stress magnetic resonance offers high spatial resolution, no radiation, and characterization of edema, scar, and alternative diagnoses. MPRI below 1.84, quantitative MPR below 2.19, and different prognostic thresholds have been proposed, but no value is universal across scanners and sequences; stress CMR requires expert protocols and analysis. Gadolinium, kidney function, artifacts, and claustrophobia may limit it.

Transthoracic Doppler primarily measures velocity in the left anterior descending artery and calculates reserve under vasodilator stress. Thresholds below 2.0 or 2.5 are used according to protocol; in the iPOWER study, a value below 2.25 identified women with a worse prognosis. Echocardiographic CFVR involves no radiation and is repeatable. It depends on the acoustic window, experience, and the assumption of a stable diameter.
Intracoronary acetylcholine assesses endothelium-dependent vasomotion with escalating doses while symptoms, ECG, and caliber are monitored. Microvascular spasm requires reproduction of pain and ischemic changes without epicardial constriction of 90 percent or greater; with such constriction, the diagnosis is epicardial spasm. The vasomotor test does not measure the same function as adenosine. A finding may coexist with abnormal CFR or resistance.

Acetylcholine testing must be performed by prepared teams after appropriate management of drugs that may mask the response. It may provoke bradycardia, atrioventricular block, atrial fibrillation, tachyarrhythmias, or persistent spasm; a meta-analysis of 12,585 patients estimated major complications at 0.5 percent with no deaths. Procedural safety depends on an expert setting. Low risk does not mean zero risk or justify testing without therapeutic consequences.
According to the 2024 ESC guidelines, in patients who remain symptomatic despite therapy, with suspected ANOCA or INOCA and impaired quality of life, invasive functional testing is recommended to identify treatable endotypes, class I level B. Doppler of the left anterior descending artery, CMR, and PET may be considered for reserve, class IIb B. The diagnostic choice follows the question and preferences. Not every patient needs the entire panel.

Treatment and prognosis

Therapy begins by explaining that there is no stenosis to correct with a stent and that small vessels may generate ischemia through different mechanisms. Measurable objectives are agreed, such as weekly episodes, nitrate use, activity, and SAQ score, while avoiding simultaneous changes that make benefit impossible to attribute. Shared decision-making reduces frustration and random polypharmacy. Warning signs remain separate from usual recurrences.
Smoking cessation, progressive activity, weight management, sleep, and stress management improve risk and capacity. Hypertension, lipids, diabetes, anemia, thyroid disease, inflammatory disorders, and other conditions are treated according to guidelines because they affect demand and microvascularization even when they are not the sole cause. Risk-factor control is necessary for everyone. Specific evidence that it alone prevents MVA events nevertheless remains incomplete.

For MVA with reduced CFR or elevated resistance, beta-blockers, calcium channel blockers, ranolazine, and ACE inhibitors are used according to heart rate, blood pressure, and comorbidities. The 2024 ESC guidelines recommend considering drugs that prevent demand ischemia for symptom control, class IIa B; anti-demand therapy reduces heart rate and oxygen consumption. Bradycardia, hypotension, asthma, and ventricular function affect the choice.
In the functional phenotype with high resting flow, control of tachycardia and demand with a beta-blocker or, in selected cases, ivabradine may be rational. Blood pressure must remain sufficient to support perfusion, and no large trials establish a universal sequence or reduction in events; the functional phenotype requires cautious interpretation. A normal resistance index does not mean absence of disease or automatic indication for a drug.

In documented microvascular spasm, calcium channel blockers are the central choice, as in other vasospastic disorders, while nitrates and nicorandil may be added according to response and availability. Nitrate efficacy is less consistent in pure MVA than in epicardial spasm; the spastic component argues against isolated empirical beta-blockade, especially with a nonselective agent. Mixed forms may require carefully titrated combinations.
ACE inhibitors may improve endothelial function and symptoms in subgroups, but the specific evidence base consists mainly of small studies. In the WISE trial, 78 women with CFR below 3 were randomized to quinapril or placebo and 61 completed 16 weeks, with improvement in CFR and angina; the quinapril evidence supports possible usefulness, not a definite effect on events. Kidney function, potassium, and blood pressure require monitoring.

Ranolazine reduces the late sodium current and may improve myocardial relaxation without substantially lowering heart rate or blood pressure. A crossover trial of 128 participants was neutral overall for symptoms and perfusion, but suggested a signal in patients with CFR below 2.5; ChaMP-CMD strengthened the concept of physiological selection. Selective use of ranolazine is a symptomatic option, not disease-modifying therapy. QT interval, interactions, and kidney or liver function must be considered.
CorMicA randomized 151 patients and showed that disclosure of coronary functional results with stratified therapy improves angina and quality of life at six months, with benefit maintained at one year. In 2025, ILIAS ANOCA confirmed improvement in the SAQ score at six months with endotyping and targeted therapy; endotype-guided care therefore has evidence for symptom benefit. Neither study was powered to demonstrate a reduction in myocardial infarction or mortality.

Not all studies are positive. CorCTCA improved diagnostic reclassification and treatment satisfaction without a clear sustained benefit for angina burden; EDIT-CMD did not show substantial improvement in symptoms or quality of life with six weeks of diltiazem, although it reduced epicardial spasm. Therapeutic heterogeneity reflects different mechanisms and measurements. A neutral average response does not exclude benefit in the appropriate subgroup.
PRIZE assessed the endothelin antagonist zibotentan in a crossover trial and did not improve exercise time, while increasing some adverse effects. WARRIOR, published in 2026, did not reduce the clinical composite with systematic prescription of a high-intensity statin, an ACE inhibitor or ARB, and aspirin versus usual care in 2,476 women with suspected ANOCA or INOCA. Indiscriminate prevention does not replace individual indications. Underenrollment, baseline therapy, and contamination limit absolute conclusions.

Aspirin is not automatic in pure MVA without atherosclerosis, myocardial infarction, PCI, or another indication because specific benefit has not been demonstrated and bleeding remains real. Statins and ACE inhibitors follow the presence of plaque, risk, blood pressure, diabetes, kidney function, and other indications, in addition to any endothelial objective. Preventive therapy is individualized. The protocol for obstructive coronary artery disease is not transferred wholesale to every patient.
Prognosis is not uniformly benign. In the COVADIS registry of 686 patients, 64 percent women, 78 major events occurred during a median follow-up of 398 days; hypertension and previous coronary artery disease were independent predictors, while women reported worse quality of life but similar event rates. Prognostic estimation integrates physiology and comorbidities. It is not inferred from pain intensity alone.

Complications

The most common complication is persistent or recurrent angina, with reduced activity, absence from work, sleep disturbance, and loss of independence. Patients may greatly restrict themselves through fear even when immediate risk is limited, promoting early tachycardia and further intolerance; physical deconditioning is recognized and treated. Rehabilitation and graded exposure first require an assessment of stability.
Urgent visits, repeated coronary angiograms, and uncoordinated medication changes increase costs and risks without necessarily clarifying the mechanism. Integrated documentation of anatomy, CFR, resistance, acetylcholine, and therapeutic response prevents every episode from restarting with a search for stenosis alone; the healthcare burden is part of morbidity. Appropriateness does not mean withholding new tests when the clinical picture genuinely changes.

Major cardiovascular events include cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure or unstable angina, but definitions and percentages vary among studies. In WISE, CFR below 2.32 distinguished a group with more events, while observational meta-analyses associate isolated CMD with increased mortality and MACE. Observational risk does not prove that raising CFR with a drug eliminates events. Promises of unproven prognostic modification must be avoided.
Reduced CFR has been associated with diastolic dysfunction and future hospitalization for HFpEF. In the Taqueti study, the combination of CFR below 2 and diastolic dysfunction identified the highest risk, but the observational design does not establish a single causal sequence; progression to HFpEF is not inevitable. Dyspnea, edema, and reduced capacity require assessment for heart failure according to its own criteria.

Microvascular and epicardial spasm may coexist, and overlap is associated with a worse prognosis in some cohorts. Prolonged episodes may cause important ischemia; syncope, documented arrhythmias, or marked ECG changes require specialist management and investigation for concomitant epicardial spasm. The mixed phenotype modifies therapy and surveillance. It is not inferred solely from rest pain.
Polypharmacy may cause bradycardia, hypotension, edema, headache, constipation, fatigue, and QT prolongation; these effects impair capacity and may be mistaken for disease progression, especially when several drugs are changed simultaneously. Drug tolerability is an outcome to be measured. Blood pressure, heart rate, ECG, kidney function, and interactions guide titration and discontinuation.

Anxiety, depression, hypervigilance, and catastrophizing may result from persistent pain and years of incomplete reassurance. Treating them improves sleep, adherence, and functional recovery, but must not be presented as refutation of valid ischemic or microvascular evidence; mental health is part of integrated care. Competent support reduces the false alternative between an organic and a psychological symptom.
A false-positive result may lead to an unnecessary label and medication, while a false negative may perpetuate symptoms and procedures. Values near the threshold, inadequate hyperemia, caffeine, a poor Doppler signal, and unstable blood pressure require technical review before a conclusion is drawn; measurement quality protects against both directions of error. The final diagnosis must state concordant data and residual limitations.

Finally, the MVA label may obscure new disease if it is applied automatically to every recurrence. Atherosclerosis may progress, and thrombosis, spontaneous dissection, embolism, myocarditis, Takotsubo syndrome, or aortic or pulmonary disease may arise; a change in pattern requires a new assessment. Continuity of care means knowing the previous course without being imprisoned by it.